Product
NT219
1 clinical trial
7 indications
Indication
Solid TumorIndication
AdultIndication
Squamous Cell Carcinoma of Head and NeckIndication
Colorectal AdenocarcinomaIndication
Metastatic Solid TumorIndication
Recurrent Solid TumorIndication
Head and Neck CancerClinical trial
A Phase 1/2 Study With Open-Label, Dose Escalation Phase Followed by Single-Arm Expansion at the Maximum Tolerated Dose to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of NT219 Injection Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck CancerStatus: Active (not recruiting), Estimated PCD: 2024-05-08